
Actithera secures $75.5m to advance radioligands
Last week, Actithera announced the closing of its series-A funding to allow for its radioligand therapy, led by investors M Ventures, Sofinnova Partners, and Hadean Ventures. The US$75.5 million will finance Actithera’s fibroblast activation protein (FAP)- …